Business Insider

Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific ...

In an effort to help more patients bring down the risk of heart attack and stroke, Amgen recently made Repatha available in the United States (U.S.) at a 60 percent reduced list price to address ...
Business Insider

Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018

THOUSAND OAKS, Calif., Nov. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of 10 scientific research abstracts, including the final report of the OSLER -1 study, ...
Reuters

Amgen profit beats Street view, will not raise prices again in 2018

(Reuters) - Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year earnings forecast, and its chief executive pledged not to raise drug prices again this ...
FierceBiotech

JPM 2022: Amgen teams up with Arrakis to destroy disease-causing RNA in $75M research deal

So far, this year's J.P. Morgan Healthcare Conference has been the go-to event for pharmaceutical companies to share their new research pals. Amgen is adding to the camaraderie with a $75 million ...